Over the last 20 years, our research has focused on investigating the underlying mechanisms by which cancers can survive and evade the effects of chemotherapy.
This research led to the identification of novel drug targets that now form the basis for innovative strategies to improve the effectiveness of the most widely prescribed cornerstone chemotherapies. CV6 Therapeutics was founded in 2013 to accelerate the development of these novel targeted small molecule therapeutics. CV6 Therapeutics’ first oncology drug, CV6–168, has completed pre–clinical development and is poised to enter clinical trials.
Uncontrolled growth and abnormal cellular behaviour are traits of cancer cells and immune cells that contribute to autoimmune and inflammatory disorders. CV6 Therapeutics is developing innovative new medicines to block the growth and control the behaviour of these abnormal cells. By doing this, we aim to develop new treatments that will make a real difference in the lives of patients and their families. We are advancing a growing pipeline of investigational therapeutics that will enhance the effectiveness of some of the most commonly used standard–of–care therapies for the treatment of cancer and inflammatory conditions.
Management and Scientific Advisory Board
- CV6 Therapeutics’ management team brings together decades of experience across both science and business disciplines.
- CV6 Therapeutics’ panel of scientific advisors is comprised of world class physicians, medicinal chemists, cancer biologists and pharmaceutical industry experts. Working in concert with our technical, business and regulatory experts, this team has been assembled to strategically support the development of the Company’s innovative pipeline.
Invest Northern Ireland
CV6 Therapeutics (NI) Limited has received an Invest NI Grant for Research and Development, supporting company innovation in services, products and processes. Part financed by the Investment for Growth and Jobs Programme for Northern Ireland 2014–2020, co–financed by the European Regional Development Fund. This project, developing novel combination therapies to overcome critical drug resistance pathways in cancer, aims to undertake highly innovative Research and Development to develop drug candidates with a potential to make chemotherapy more effective. The project also aims to develop new therapies which will be used in conjunction with existing chemo–therapy drugs to increase their effectiveness.
Queen’s University Belfast
CV6 Therapeutics (NI) Ltd has chosen to partner with the Centre for Cancer Research and Cell Biology at Queen’s University Belfast as part of a multidisciplinary collaboration with Invest NI, adding to the growing momentum of successful academic–industrial partnerships designed to accelerate advances in human health. CV6 Therapeutics (NI) Ltd is developing novel therapeutic agents designed to make chemotherapy more effective. The collaboration with QUB will complement the drug development effort by using the resources and expertise at the Centre for Cancer Research and Cell Biology to conduct cutting edge research that seeks to further unravel the molecular mechanisms that underpin the concept of chemotherapy enhancement. In the emerging era of precision medicine, the successful identification and validation of biomarkers will help maximise the clinical impact of these new therapeutic agents in early phase clinical trials by directing them towards patients who are likely to benefit.
- Entered in to a collaboration agreement with CCRCB, QUB in 2015 with additional support from InvestNI.
- Internationally recognised Scientific and Medical Advisory team
- First oncology drug candidate, the novel dUTPase inhibitor CV6–168, is about to enter Phase I clinical trials.
- CV6–168 enhances the effectiveness of the most widely used cancer drugs
- Inflammatory disease program is in pre–clinical development phase.